Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2014 07:30 ET | Source: Advaxis

Advaxis Announces Filing for USDA Product License

PRINCETON, N.J., July 2, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that a product license from the United States...
June 30, 2014 08:56 ET | Source: Advaxis

Advaxis's Cancer Immunotherapy Featured on CBS News

PRINCETON, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary immunotherapy, was...
June 25, 2014 08:30 ET | Source: Advaxis

Advaxis to be Added to Russell Microcap Index

PRINCETON, N.J., June 25, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company will be added...
June 23, 2014 07:30 ET | Source: Advaxis

Advaxis Receives Notice of Allowance From U.S. Patent Office for Two Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2

PRINCETON, N.J., June 23, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has received notice of allowance from the...
June 16, 2014 08:30 ET | Source: Advaxis

Advaxis Evaluates Higher Dose and Repeat Cycles of ADXS-HPV in Phase 1/2 Cervical Cancer Trial

PRINCETON, N.J., June 16, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the Georgia Regents...
June 12, 2014 07:30 ET | Source: Advaxis

Advaxis to Present at BIO International Convention

PRINCETON, N.J., June 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, today announced that the Company will present at the BIO...
June 10, 2014 06:30 ET | Source: Advaxis

Advaxis Provides Business Update

PRINCETON, N.J., June 10, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, today announced that its request for an End-of-Phase 2...
June 09, 2014 07:30 ET | Source: Advaxis

Advaxis Announces Business Update Conference Call

PRINCETON, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announces that its management team will host a corporate...
June 06, 2014 07:30 ET | Source: Advaxis

Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in Canine Osteosarcoma

PRINCETON, N.J., June 6, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that principal investigator, Nicola Mason,...
June 04, 2014 08:00 ET | Source: Advaxis

Data Published by Researchers at the National Cancer Institute Further Identifies How Advaxis's Lm-LLO Immunotherapy Eradicates Tumors

PRINCETON, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced the publication of preclinical research with its...